Literature DB >> 12355361

Pneumococcal carriage and otitis media induce salivary antibodies to pneumococcal capsular polysaccharides in children.

Birgit Simell1, Terhi M Kilpi, Helena Käyhty.   

Abstract

Mucosal immunity likely plays an important role in the defense against Streptococcus pneumoniae. This study examined whether pneumococcal carriage and acute otitis media induce mucosal antibodies to pneumococcal capsular polysaccharides (Pnc-PSs) of types 1, 6B, 11A, 14, 19F, and 23F. Immunoglobulin (Ig) A, IgG, and secretory (S) Ig anti-Pnc-PS antibodies were measured by enzyme immunoassay in the saliva of children at ages 6, 12, 18, and 24 months and were analyzed in relation to the previous pneumococcal findings. A larger proportion of IgA-positive samples and higher concentrations of type-specific IgA antibodies were detected in samples of children with pneumococci of the given types cultured before sampling from nasopharyngeal samples or middle-ear fluid, compared with children who had cultures negative for pneumococci of the indicated types or of all types. The IgA and S-Ig concentrations correlated strongly, which suggests that the anti-Pnc-PS IgA was secretory. Salivary anti-Pnc-PS IgG was detected only rarely.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12355361     DOI: 10.1086/344235

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Antibody-enhanced pneumococcal adherence requires IgA1 protease.

Authors:  Jeffrey N Weiser; Deborah Bae; Claudine Fasching; Ronald W Scamurra; Adam J Ratner; Edward N Janoff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-17       Impact factor: 11.205

Review 2.  Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.

Authors:  Q Zhang; A Finn
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

3.  Subclass distribution of natural salivary IgA antibodies against pneumococcal capsular polysaccharide of type 14 and pneumococcal surface adhesin A (PsaA) in children.

Authors:  B Simell; T Kilpi; H Käyhty
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

4.  Host and bacterial factors contributing to the clearance of colonization by Streptococcus pneumoniae in a murine model.

Authors:  Annemarie M C van Rossum; Elena S Lysenko; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

5.  Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization.

Authors:  Tera L McCool; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

6.  Effect of presumptive co-trimoxazole prophylaxis on pneumococcal colonization rates, seroepidemiology and antibiotic resistance in Zambian infants: a longitudinal cohort study.

Authors:  C J Gill; V Mwanakasale; M P Fox; R Chilengi; M Tembo; M Nsofwa; V Chalwe; L Mwananyanda; D Mukwamataba; B Malilwe; D Champo; W B Macleod; D M Thea; D H Hamer
Journal:  Bull World Health Organ       Date:  2008-12       Impact factor: 9.408

Review 7.  Serotype-independent pneumococcal vaccines.

Authors:  Eliane Namie Miyaji; Maria Leonor Sarno Oliveira; Eneas Carvalho; Paulo Lee Ho
Journal:  Cell Mol Life Sci       Date:  2012-12-27       Impact factor: 9.261

8.  Development of antibodies to PspA families 1 and 2 in children after exposure to Streptococcus pneumoniae.

Authors:  Merit M Melin; Susan K Hollingshead; David E Briles; Mika I Lahdenkari; Terhi M Kilpi; Helena M Käyhty
Journal:  Clin Vaccine Immunol       Date:  2008-08-27

9.  Salivary antibodies induced by the seven-valent PncOMPC conjugate vaccine in the Finnish Otitis Media Vaccine Trial.

Authors:  Anu Nurkka; Mika Lahdenkari; Arto A I Palmu; Helena Käyhty
Journal:  BMC Infect Dis       Date:  2005-05-27       Impact factor: 3.090

10.  Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life.

Authors:  Gerwin D Rodenburg; Elisabeth A M Sanders; Elske J M van Gils; Reinier H Veenhoven; Tomasz Zborowski; Germie P J M van den Dobbelsteen; Andries C Bloem; Guy A M Berbers; Debby Bogaert
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.